Prospective Evaluation of Fecal Calprotectin As A Screening Biomarker for Colorectal Neoplasia

Abstract

In this cohort of colonoscopy patients at above average risk, fecal calprotectin was a poor screening biomarker for colorectal neoplasia. Further investigation of tumor-derived, rather than blood-based, biomarkers may be a more rewarding approach to stool screening for colorectal neoplasia.

Evaluation of Calgranulin B in Stools from the Patients with Colorectal Cancer

“…4 Consequently, for the CRC screening, fecal calprotectin test is not better than hemoglobin immunochemical FOBT. 21,22 Calprotectin was not a useful stool marker for CRC. However, so far there has been no information on the level of individual calgranulin A and B in CRC patients' stools.…”

S3-Guidelines Colorectal Cancer 2004

“…Die jährliche war der zweijährigen Testung in Bezug auf die Reduktion der Mortalität in einer Studie eindeutig überlegen [354]. Immunologische Stuhltests auf Albumin oder Calprotectin sind für das Screening nicht geeignet [336]. Ebenso reicht die Datenlage zur M2-PK-Bestimmung im Stuhl nicht aus, um einen Einsatz außerhalb von Studien zu rechtfertigen [223].…”

Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease

“…The excretion of Indium-111-labelled white cells has been suggested to be the 'gold standard' of disease activity in IBD, but the high cost and hazardous radioactive exposure have limited its use to research purposes only. In several studies it has been shown that faecal calprotectin correlates well with disease activity in IBD patients and it has been concluded that it is a convenient non-invasive marker of inflammation in such patients (3)(4)(5)(6). It has also been suggested that faecal calprotectin could be a useful marker for determination of mucosal healing (7).…”